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Abstract 
 
 
Depression is a condition with various modes of treatment, including pharmacotherapy, 
psychotherapy, and some combination of each. The role of psychotherapy in the treatment of 
depression relative to the role of pharmacotherapy is not well understood, and guidelines for 
psychotherapy in the primary care setting differ from guidelines for specialty care. There is little 
evidence about the circumstances in actual practice that affect the use of psychotherapy in 
conjunction with pharmacotherapy. 
 
We retrospectively identify the most important factors associated with the use of 
psychotherapy in combination with pharmacotherapy in the treatment of depression. Specifically, 
we study provider choice, health plan characteristics, and patient characteristics. 
 
We use a comprehensive medical and pharmacy claims data sample of 1,023 individuals 
during 1992–1994. We select persons prescribed with an antidepressant medication and 
diagnosed with a depressive disorder by a primary care physician, psychiatrist, or non-physician 
mental health specialist. Controlling for depression diagnosis and severity, comorbidity, and 
demographics, we examine the role of provider type and plan benefit characteristics. We study 
the intensity of psychotherapy using zero-inflated count regression, the intensity of 
pharmacotherapy using truncated count regression, and the likelihood of relapse of depression 
using logistic regression. 
 
Patients initially seeing a psychiatrist receive more than double the amount of 
psychotherapy and slightly more pharmacotherapy than patients of other providers. An additional 
prescription for antidepressant medication reduces by five percent the likelihood of relapse into 
depression, but the amount of psychotherapy does not affect relapse. Patients seeing a 
psychiatrist are half as likely to relapse, independent of any effect of psychotherapy. Case 
management and coinsurance rates do not affect the amount of psychotherapy, but the presence 
of case management has a positive effect on the amount of pharmacotherapy and on the 
likelihood of relapse. 
 
We find no discernible pattern of complementarity or substitution between 
pharmacotherapy and psychotherapy across providers. Although the amount of psychotherapy 
provided in conjunction with medication does not affect the rate of relapse to depression, 
psychotherapy may nonetheless provide beneficial outcomes not studied here. Choice of a 
psychiatrist reduces the likelihood of relapse, independent of the number of psychotherapy 
sessions and antidepressant prescriptions. The effect of provider choice on relapse could be an 
artifact of differences in provider follow-up practices or could represent a difference in provider 
skills. Managed care strategies do not appear to reduce the intensity of depression treatment, but 
case management does increase the likelihood of relapse. 
 
Pharmacotherapy and psychotherapy appear to be neither substitutes nor complements in 
the treatment of depression, suggesting that treatment is individualized. Choice of psychiatrist as 
the initial provider appears to reduce the likelihood of relapse, suggesting models of coordinated 
care may be beneficial. The link between psychiatrists and more psychotherapy is consistent with 
the hypothesis that patients resistant to treatment may nonetheless receive high quality care. 
  
 
 
Managed care tools such as case management and coinsurance rates do not appear to 
restrict the use of either psychotherapy or pharmacotherapy. The association of case management 
with an increased likelihood of relapse suggests that plan characteristics can affect outcomes. 
 
Our study focuses on psychotherapy combined with medication and does not 
psychotherapy alone in the treatment of depression, which may be a preferred mode of treatment 
for some. Outcomes other than relapse, as well as costs, should also be considered. Our findings 
that psychiatrists are associated with a decreased likelihood of relapse and that case management 
is associated with an increased likelihood of relapse despite a correlation with greater 
pharmacotherapy intensity present avenues for additional study. 
 
Key Words: depression, psychotherapy, pharmacotherapy, relapse, count models, zero inflated 
negative binomial regression 
 
 
 
1. Introduction 
The role of psychotherapy in the treatment of depression has been a subject of some 
uncertainty in recent years as pharmacotherapies have proliferated. A recent study has shown 
that the proportion of individuals treated with psychotherapy has declined even though the rate of 
outpatient treatment for depression has increased (Olfson et al. 2002). Although psychotherapy 
alone is recognized as an efficacious treatment, it is often provided in combination with 
antidepressant medication in the treatment of depression. Psychotherapy in conjunction with 
medication may be beneficial not only as a direct treatment of the depressive disorder and its 
symptoms but also as an aid both to medication compliance (Paykel 1995) and family support of 
treatment (Miller 1996). However, although combined treatment has been shown to be more 
efficacious than unimodal treatment in specific contexts (Keller et al. 2000), generally the 
indications for combination treatment are unclear, and guidelines for treatment in the primary 
care setting differ from guidelines for psychiatric specialty care (Persons 1996). Here we 
examine how pharmacotherapy and psychotherapy are paired in practice across providers in the 
treatment of depression and the ultimate consequences of the mix of pharmacotherapy, 
psychotherapy, and provider for relapse into depression. 
The circumstances in actual practice under which psychotherapy is best combined with 
antidepressant medication are not well understood. Aside from provider and patient preferences, 
additional factors can affect the use of psychotherapy, such as availability and cost (Thase 1997). 
Previous work has identified a need for examination of the practice of psychotherapy, including 
psychotherapy with concurrent pharmacotherapy, as well as characterization of patients in terms 
of diagnosis, severity, comorbidity, and demographics (Clarkin 1996). 
 
 
Other work has suggested that characteristics of the health care system can affect the use 
of psychotherapy in treating depression. Data from the Medical Outcomes Study showed that 
depressed patients of general medical clinicians receive less counseling than patients of mental 
health specialists and that health plan prepayment is associated with lower counseling rates 
(Meredith et al. 1996). In addition, although the cost-containment incentives of managed care 
organizations have been cited as a potential reason for reductions in the use of psychotherapy, 
some observers have suggested that psychotherapy, if shown to be cost-effective, might be more 
compatible with managed care than with traditional health insurance arrangements (Sharfstein 
1999). Indeed, in the context of severe mental illness, psychotherapy has been associated with 
reduced costs (Gabbard 1997). Thus, the relationship between the use of psychotherapy and 
managed care strategies is not clear. 
Recent evidence suggests that psychotherapy and pharmacotherapy are productive 
complements in treating depression, meaning that they have similar therapeutic effects, ceteris 
paribus (DeRubeis 1999). However, in clinical practice they need not be used in isolation (as 
therapeutic substitutes in depression treatment), but rather together (as complementary 
treatments). Our results shed light on the degree to which, in practice, psychotherapy and 
pharmacotherapy are substitutes, complements, or appear unconnected quantitatively. 
Specifically, we attempt to identify retrospectively the most important factors associated with the 
use of psychotherapy in combination with medication in the treatment of depression using a 
claims data sample of persons diagnosed with depression and receiving a prescription for an 
antidepressant medication to study how psychotherapy is used in conjunction with 
pharmacotherapy.  
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 Our results suggest that patients initially seeing a psychiatrist get substantially more 
psychotherapy and slightly more pharmacotherapy than patients initially seeing other non-
psychiatrist providers of anti-depression care. We find no evidence that the two types of 
therapies are used in conjunction or that more of one is used in place of less of the other therapy 
in depression treatment. Concerning the downstream benefits of pharmacotherapy and 
psychotherapy, our results indicate that pharmacotherapy lessens the likelihood of relapse into 
depression, but that psychotherapy does not affect relapse; however patients seeing a psychiatrist 
are less likely to relapse net of any effect of psychotherapy. 
2. Methods 
 Our objective is to disentangle the relative quantitative importance of factors influencing 
the intensity of psychotherapy in individuals treated for depression with antidepressant 
medication. We use a retrospective claims database of persons diagnosed with depression and 
treated with antidepressant medication with or without psychotherapy. Using multivariate 
statistical models that are appropriate for dependent variables that take on non-negative integer 
values and that may also be truncated, we assess whether the factors influencing psychotherapy 
are jointly determined with the intensity of medication use. Finally, we examine the relationship 
among psychotherapy, pharmacotherapy, and a downstream outcome of interest in the treatment 
of depression, the likelihood of relapse. 
2.1 Data and Variable Definitions 
Our data, which come from the MarketScan database, contain comprehensive medical 
and pharmacy claims data for about 700,000 employed persons and their families who worked in 
20 different self-insured Fortune 500 companies (The MEDSTAT Group, Ann Arbor, MI). 
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Health insurance benefits offered by employers include indemnity and managed care plans that 
were dominated by preferred provider organizations. The particular MarketScan information 
we use centers on claims data for continuously enrolled individuals and their plan benefit 
information from 1992 through 1994. 
Available claims information covers eight quarters post-depression diagnosis and two 
quarters pre-depression diagnosis. We select antidepressant recipients diagnosed with a 
depressive disorder by a primary care physician, a psychiatrist, or a non-physician mental health 
specialist. To identify new treatment episodes we exclude persons with any claims for 
psychotherapy or antidepressants in the six-month period prior to the diagnosis of depression. 
We include only people with information about plan benefit characteristics. Our final sample size 
used in estimation is 1,023. 
Table 1 lists the variables of interest in the study sample. In addition to demographic 
information about the patient’s age, sex, and the number of comorbid conditions, we examine 
effects of the specific depression diagnosis and the type of provider associated with the initial 
depression diagnosis. We also attempt to account for propensity to use health care and overall 
health by including non-psychiatric costs in the quarter prior to the diagnosis. We account for the 
intervening influence of the number of anxiolytic prescriptions filled after the depression 
diagnosis, which could correspond to the level of psychiatric distress, be an indicator of 
prescription-filling behavior, or measure inappropriate treatment of depressive symptoms. To 
examine the effect of characteristics of the health plan and to purify the estimated effects of 
provider on outcomes of interest in a multivariate setting, we include as control variables the 
outpatient psychiatric coinsurance rate and whether the health plan employed case management 
practices. We identify relapse or recurrence of depression when the claims data include any of 
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the following: a new episode of drug therapy follows a gap of six or more months in medication 
claims, a suicide attempt, a psychiatric hospitalization; a mental health related emergency 
department visit, or electroconvulsive therapy.1    
2.2 Data Analytic Procedures 
To study the use of psychotherapy and pharmacotherapy in some quantitative detail, we 
expand on simple univariate comparisons in by employing multivariate models of the number of 
psychotherapy visits and antidepressant prescriptions that account for the substantial number of 
nonusers of psychotherapy and the fact that all patients had at least one antidepressant 
prescription. Our list of categorical explanatory variables includes depression diagnosis 
indicators, with Depression Not Otherwise Specified as the reference category, and diagnosing 
provider indicators, with Primary Care Physicians as the reference category. The amount of 
psychotherapy is determined by the number of psychotherapy visits after the depression 
diagnosis, and the amount of pharmacotherapy by the number of antidepressant prescriptions. 
Because the dependent variables we study are each a non-negative integer we use count data 
models rather than standard regression models in which the dependent variable is assumed to be 
a continuous variable.2 
The Poisson regression model is the most basic count model, but it invokes the restriction 
of equality between mean and variance, termed equi-dispersion. Because preliminary results 
show that the conditional mean and variance are unequal for each of the two therapies we study 
in our sample, we employ the more general Negative Binomial multivariate model, which is a 
generalization of the Poisson model that allows for overdispersion (the conditional variance 
exceeds the conditional mean) and has been productively applied to models of health care 
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utilization (Cameron and Trivedi 1998; Freund, Kniesner, and LoSasso 1999; Jones 2000; 
Winkelmann 2000). 
 Expressed algebraically, the conditional mean value of a therapy level in a sample where 
i indexes a case of depression is 
 ( | ) exp( )i i i iE y x b xλ ′= = ,               (1) 
where b is the vector of parameters to estimate that determine the marginal effect of an 
independent variable, x, on the discrete value of therapy incidence, y. Additionally, the negative 
binomial count model includes an overdispersion parameter, δ, that parameterizes the prevalent 
form of heteroskedasticity where the conditional variance exceeds the conditional mean, λ, 
which is prevalent in count data such that 
 var( | ) (1 )i i i iy x λ λδ= + .               (2) 
Equation (2) illustrates how the negative binomial specification nests inside it the Poisson model, 
and that if  then the Poisson count model appears. ˆ 0δ =
An additional complexity common in models of counts is a large number of zero values. 
In our case about 47 percent of the sample had no claim for psychotherapy, and we attempt to 
account for the high proportion of patients not receiving psychotherapy in the statistical model. 
Although the Negative Binomial model accommodates a large number of zeros, we also estimate 
variations of the Negative Binomial model that further adjust for so-called excess zeros in the 
sample termed the zero-inflated Negative Binomial model. The ZINB model adds what is termed 
a splitting parameter, q, that is the proportion of zero use that will occur no matter what the 
values of the independent variables might be (some people will never submit to psychotherapy). 
 ( | ) (1 ( ))i i i iE y x q xλ= −                (3) 
and 
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var( | ) (1 )[1 ( )]i i i i i iy x q qλ λ δ= − + + .              (4) 
Using the same list of explanatory variables we also examine models of the intensity of 
pharmacotherapy for depression where the dependent variable is the number of antidepressant 
medication prescriptions filled. To expand upon a simple comparison of means we again use a 
multivariate count regression model. However, because our sample of depressed persons is 
constructed by locating patients with at least one antidepressant prescription, we must employ a 
model that accounts for truncation at zero.3 We therefore use a truncated negative binomial 
model to examine the marginal effect of provider type on anti-depressant medication use. 
Along with the count regressions for psychotherapy, our regression for pharmacotherapy 
reveals whether intensity of pharmacotherapy seems to complement, substitute for, or is largely 
independent of the amount of psychotherapy. If psychotherapy complements pharmacotherapy, 
then the number of psychotherapy visits should increase with the number of antidepressant 
prescriptions. If they are substitutes, then the number of psychotherapy visits should decline as 
the number of prescriptions increases. If neither a positive nor a negative relationship occurs 
between the two therapies, then we consider decisions to use psychotherapy and 
pharmacotherapy largely independent.  
Lastly we examine the relative importance of the components of anti-depression 
treatment on treatment success measured by the likelihood of a relapse. For ease of interpretation 
we use the familiar binary (y = 0, 1) logit specification with 
 Prob(Relapse) = Prob(y = 1) = /(1 )x xe eβ β′ ′+ ,            (5) 
where we are concerned with the estimates of β to use in constructing case-mix adjusted effects 
of the regressors related to the specialty of treatment provider and amounts of pharmacotherapy 
versus psychotherapy. In our data relapse means that the person subsequently experienced a new 
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episode of anti-depressant therapy, a suicide attempt, psychiatric hospitalization, a mental health 
related emergency department visit, or electroconvulsive therapy, a measure previously shown 
responsive to changes in the quality of care (Melfi et al. 1998, Sood et al. 2000). 
 Before discussing our results it is important to note that the regression coefficients, b in 
Equation Psychotherapy in Antidepressant Patients n (1) and β in Equation (5) are not the objects 
of interest, because they are not themselves the estimated effects of a change in an independent 
variable. All of the models we estimate are non-linear index transformations of the regressors 
with general form  so that marginal effects (ME) of interest must be evaluated at a 
particular set of values for x, which we generally set equal to 
( ( ))y G f x=
x . For a continuous regressor ME 
= , so that for the negative binomial models of pharmacotherapy and psychotherapy ME 
=
ˆĜ f′ ′
ˆˆ( )x bλ  and for the relapse logit the marginal effect is ME = ˆˆ ˆ( )(1 ( )P x P x β− , where P = Prob(y 
= 1). For a discrete regressor, say provider type, ME = 
ˆ ˆˆ ˆ ˆ ˆˆ ˆ) ( 1)) ( ( 0)) ( )(1 ( )y x G f x P x P x ˆ( 1y x 0) ( (G f x β= − = − = ≅ −= = . In the empirical results we 
focus the discussion on the estimated marginal effects of provider type on the numbers of 
psychotherapy visits and anti-depressant prescriptions and on the marginal effects of the intensity 
of pharmacotherapy, psychotherapy, and provider type on treatment success measured by the 
probability of a relapse. 
3. Results 
Table 1 presents the descriptive statistics for the entire sample and is stratified by the type 
of provider making the initial diagnosis of depression. As in our prior research (Kniesner, 
Powers, and Croghan 2002), the specialty of the first provider is significantly associated with the 
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mix of treatment patients subsequently receive. Patients diagnosed by psychiatrists average about 
11 claims for psychotherapy, while patients of non-physician mental health specialists average 
about Psychotherapy in Antidepressant Patients. 
Five claims, and patients diagnosed by primary care physicians average three to four 
psychotherapy claims. Inter-provider differences in case-mix, which could reflect diagnostic 
patterns or real differences in the types of patients who seek care from specific providers, are 
such that psychiatrists are the main provider of treatment for cases of single episode and 
recurrent major depression while non-physician mental health specialists are the main provider 
of treatment for cases of dysthymia and reactive depression. Psychiatrist patients also receive 
more prescriptions for anxiolytics and are less likely to relapse than those seeing other providers. 
Overall, about three fourths of the sample received at least four prescriptions in the first six 
months of treatment, and there were no differences among providers. Because univariate 
comparisons do not reveal fully the degree of differences in case-mix among various providers, 
we proceed to control for case-mix details in order to identify better the role of provider type in 
the use of psychotherapy, pharmacotherapy and treatment success. 
3.1 Psychotherapy Visits 
 Table 2 presents the zero-inflated negative binomial (ZINB) count model of the number 
of psychotherapy visits. We include both model coefficients and marginal effects computed at 
the means of the independent variables. Both the estimated overdispersion parameter ( δ̂ ) and the 
estimated zero-inflation parameter (which is a function of q ) are significant statistically, which 
means that the data reject both the simpler Poisson specification and the basic negative binomial 
specification in favor of the ZINB count model form.
ˆi
4 Concerning the variables controlling for 
case-mix across providers, a diagnosis of recurrent major depressive disorder is significantly and 
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positively related to the number of psychotherapy visits, resulting in approximately four to five 
additional psychotherapy visits, such that the number of visits for a major depressive disorder is 
about twice the mean. The effects of all other types of depression are small and insignificant 
statistically as are the influences of age and gender on psychotherapy. 
Neither the psychiatric coinsurance rate nor the presence of case management in the 
health insurance plan are statistically significant predictors of the amount of psychotherapy.5 
Using the mean amount of psychotherapy as a comparison point, ceteris paribus the existence of 
case management lowers the amount of psychotherapy by about 9 percent and doubling the 
coinsurance rate on mental health care reduces psychotherapy by about 7 percent, but insurance 
plan characteristics appear to be statistically weak determinants of the number of psychotherapy 
visits. 
Because provider type appears related to the subsequent mix of treatments, a focal point 
of our research effort is whether there is a statistically significant differential effect of provider, 
ceteris paribus, on the use of psychotherapy. If the amount of psychotherapy is a substitute for 
pharmacotherapy, then it follows that providers who use more psychotherapy should use less 
pharmacotherapy. Adjusting for case-mix, diagnosis by a psychiatrist is associated with 
approximately six more psychotherapy visits than if the diagnosis is by a primary care 
physician.6 The result is quite different for diagnosis by non-physician mental health specialists. 
In contrast to the results for psychiatrists, there is a quantitatively small but insignificant increase 
in the use of  psychotherapy subsequent to an initial diagnosis by a non-physician mental health 
specialist. After adjusting for case-mix, diagnosis by a mental health specialist does not result in 
any additional psychotherapy visits than does diagnosis by a primary care physician. Finally, we 
note that the case-mix adjusted differential in the amount of psychotherapy in Table 2 between 
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psychiatrists and other providers is about the same as the unadjusted difference in Table 1; 
patients whose initial providers were psychiatrists got about twice the psychotherapy as patients 
whose initial providers of anti-depression therapy were general medical practitioners or 
non-physician mental health specialists. 
3.2 Anti-depressant Medication 
 The results for the truncated count model of anti-depressant prescriptions are presented in 
Table 3. The most striking result is that the presence of case management in the health plan is 
significantly associated with the number of antidepressant prescriptions, increasing the number 
of prescriptions by more than three. Using the mean as a point of reference, case management 
increases the intensity of pharmacotherapy by about 30 percent. No other covariates had a large 
statistically significant estimated marginal effect. The most important result to emerge from our 
truncated negative binomial count model of anti-depression pharmacotherapy is that the 
case-mix adjusted results for inter-provider differences mimic the unadjusted results of Table 1. 
We find no differences across the initial provider in the amounts of anti-depressant prescriptions 
that patients fill.7 
3.3 Relapse 
 One way to assess the success or failure of anti-depression treatment is by examining 
whether a person receives any therapy at all or discontinues therapy early, failing to complete 
and adequate amount of therapy according to recommended guidelines (Dobrez et al. 2000; 
Kniesner, Powers, and Croghan 2002). Another way is to examine the downstream consequences 
of therapy by examining whether a patient suffers a relapse of depression. In our data about 22 
percent of patients suffer a relapse. Table 4 presents logit coefficient estimates for how intensity 
of treatment and provider type influence the probability of a relapse, ceteris paribus. 
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 The most notable results concerning treatment success as indicated by a reduced 
likelihood of a relapse relate to a subtle aspect of having a psychiatric provider. In Table 4 we 
capture treatment in three dimensions: the amount of psychotherapy, the amount of 
pharmacotherapy, and the type of treatment provider. Remember that the count regression results 
in earlier tables had patients of psychiatrists receiving significantly more psychotherapy. Thus, 
one way a psychiatrist could affect the success of treatment for depression was through greater 
amounts of psychotherapy. The results in Table 4 reveal that the number of psychotherapy visits 
does not affect the likelihood of a relapse. 
Although the amount of psychotherapy does not affect relapse, the amount of 
pharmacotherapy does affect relapse in our data. Using the mean as a reference point, an extra 
anti-depressant prescription lowers the probability of relapse by approximately 4 to 5 percent 
(−0.01/0.22). Our results in Table 3 indicated no differences in the amount of pharmacotherapy 
patients receive across providers; however, there is no direct effect of having a psychiatric 
provider operating through differential amounts of anti-depression medication. 
What we find is more subtle. Holding psychotherapy visits and anti-depressant 
prescriptions constant, having a psychiatric initial provider lowers the probability of relapse by 
almost 50 percent using the mean likelihood of relapse as a reference point 
( / 0.109 / 0.223 0.49ME P = − = ). In our data there appears to be a benefit to having a psychiatric 
provider, in terms of reducing the chance of relapsing into depression, that is over and above the 
measured amounts of psychotherapy and pharmacotherapy psychiatrists provide relative to other 
providers. 
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4. Discussion 
 Our research objectives have centered on understanding any connections among the 
amounts of psychotherapy received by depressed patients who also receive an antidepressant 
with an eye for several questions of medical interest. Do there appear to be significantly different 
amounts of psychotherapy across providers, how large are the inter-provider differences in 
psychotherapy, and are psychotherapy and pharmacotherapy used as substitutes or complements 
in the treatment of depression? Finally, are there quantitatively important inter-provider 
differences in anti-depression treatment success as measured by relapse likelihood and how is 
any difference related to inter-provider differences in the amounts of pharmacotherapy versus 
psychotherapy? 
 We find that after adjusting for case-mix psychiatrists’ patients receive almost twice the 
number of psychotherapy visits but fill no more prescriptions for anti-depressant medication than 
the patients of general medical providers or non-physician mental health specialists. In the sense 
that psychiatrists’ patients get more psychotherapy than other providers’ patients but no more or 
less pharmacotherapy, there is no pattern of complementarity or substitution of one type of 
therapy for the other across providers. It appears that decisions regarding use of psychotherapy 
and pharmacotherapy are largely independent. 
 Although the research presented here generally agrees with prior research there are 
patterns of treatment we observe that are somewhat surprising. For example, although the first 
treatment for depression appears to depend largely on the specialty of the provider at the point of 
entry (Powers et al. 2000), the number of visits and the number of prescriptions appears 
independent of who first diagnosed a patient’s depression. The only exception to the 
diagnoser-treatment pattern is the finding that psychiatrists use more psychotherapy than other 
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providers; whether a patient first entered care through a general medical doctor or a non-
physician specialist makes no difference in the relative amount of psychotherapy and 
pharmacotherapy received. 
 Our research has several implications for research, clinical practice, and mental health 
policy. The notion that receiving treatment from psychiatrists may be associated with reductions 
in the incidence of relapse is provocative, but we must acknowledge a possible confound 
imposed by how relapse is identified here. Specifically, relapse here means that a new “clean” 
period with no evidence of pharmaco- or psychotherapy occurs between two episodes of 
medication treatment. However, we could fail to observe such a gap in treatment because of the 
increase in the number of psychotherapy visits associated with psychiatrists. Suppose, for 
example, that psychiatrists are more likely to see patients intermittently in follow up for a prior 
episode. If the frequency of follow up visits is every three months or more, then we do not 
observe a “clean” period and thus have no opportunity to observe a relapse even if one occurs 
clinically. Thus, our results regarding psychiatrists should be interpreted with caution but provide 
an opportunity to investigate further the relationship between provider type and relapse. 
 As is true for other studies that rely on MarketScanTM data, we report relative high levels 
of quality of pharmacotherapy. Nearly three in four patients in our study received care consistent 
with a measure used in prior research to monitor adherence to clinical practice guidelines. The 
relatively high baseline in mind, it appears that psychiatrists are more likely than other providers 
to offer additional psychotherapy to their patients. Our findings of a link between initial provider 
and psychotherapy are consistent with the hypothesis that the additional psychotherapy may be 
used for patients whose symptoms are resistant to treatment but who nonetheless may receive 
high quality treatment, which is another line of research to pursue. 
 14
 
 Case management is utilized by about a third of the plans studied here and is associated 
with more prescriptions. Because the case management identified in MarketScanTM represents a 
form of utilization review designed to limit care to those most in need, we hypothesize that plans 
which make use of such a cost-containment tool may also utilize quality improvement strategies 
that will result in better care. Because we cannot explicitly control for depression severity in our 
study, our finding of a positive correlation between case management and the probability of 
relapse might suggest that plans target case management toward patients who are more severely 
depressed and, therefore, more likely to relapse.  Our finding of a positive link between case 
management and pharmacotherapy intensity represents both an opportunity for research and an 
example for clinical practice.    
 Finally, we point to the finding that pharmacotherapy and psychotherapy appears to be 
used independently and not as substitutes or complements. Because the two treatments have 
similar efficacy rates, economists have tended to view them as perfect substitutes. We suggest, 
however, that physicians appear to apply the two therapies on an individual basis, perhaps 
attempting to individualize treatment based on need and patient preferences, a worthy if difficult 
goal. 
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1. For another example of a similar claims-based method of identifying relapse see Sood, et 
al (2000). 
 
2. OLS is clearly a misspecified functional form as the dependent variable is both bounded 
and bunched at zero. Alternatives to count models include ordered probit, Tobit, or an 
exponential functional form estimated with non-linear least squares. For empirical 
examples see Delgado and Kniesner (1997) and for discussion of the relative strengths 
and weaknesses of alternative models see Cameron and Trivedi (1998). 
 
3. Adjusting for truncation involves rescaling the likelihood that the pharmacotherapy 
dependent variable takes on any particular value by the inverse of the probability of y > 0 
(Greene 1998). 
 
4. The zero generating process was modeled as a logistic function of all x’s. Changing the 
list of regressors or functional form of the zero generating process proved uninformative. 
The estimated zero inflation statistic in Table 2 is the Vuong (1989) statistic that is used 
to check the non-nested hypothesis whether the zero-inflated negative binomial model 
detects excess zeros after controlling for overdispersion (Greene 2000). When a ZINB 
model is supported by the data the absolute value of the computed Vuong statistic is at 
least 2.0. As a point of reference the estimated marginal effect of psychiatrist is about 15 
percent smaller in a model where possible zero inflation is ignored incorrectly in our 
data. 
 
5. We note that lack of a coinsurance rate effect is driven by the fact that the rate varies little 
across the patients of primary care physicians and other mental health specialists. A 
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separate count regression for only the patients of psychiatrists shows a significantly 
negative coinsurance rate effect on psychotherapy visits such that a doubling of the 
coinsurance rate leads to 25 percent fewer visits. The possibility of heterogeneity in the 
effect of health care plan characteristics across providers remains an interesting issue for 
future research. 
 
6. As a basic robustness check we estimated the psychotherapy model in Table 2 using 
Tobit regression. The results were similar in that the estimated marginal effect of having 
a psychiatric provider was a statistically significant 6.2 additional visits with no 
significant difference for non-physician mental health specialist. 
 
7. As a basic robustness check we also estimated the pharmacotherapy model in Table 3 
using truncated normal regression (Greene 2000). The results were similar in that there 
were also no statistically significant differences across providers in the number of anti-
depressant prescriptions filled. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Descriptive Statistics Stratified by Provider – Mean (Standard Deviation) 
Variable 
 
 
 
Total 
Psychiatrist 
(n = 272) 
Non-Physician 
Mental Health 
Specialist 
(n = 163) 
Primary Care 
Physician 
(n = 588) 
Psychotherapy Visits 5.727 
(10.262) 
10.882 
(12.726) 
5.098 
(8.630) 
3.517 
(8.409) 
Antidepressant Prescriptions 11.413 
(9.255) 
12.456 
(9.815) 
11.123 
(9.459) 
11.010 
(8.903) 
Anxiolytic Prescriptions 2.895 
(7.658) 
4.272 
(9.905) 
3.160 
(9.953) 
2.185 
(5.299) 
Relapse 0.223 
(0.416)  
0.154 
(0.362) 
0.233 
(0.424) 
0.252 
(0.434) 
4+ Antidepressant Prescriptions 0.765 
(0.424) 
0.739 
(0.440) 
0.785 
(0.412) 
0.772 
(0.420) 
Log Medical Costs 8.031 
(1.341) 
8.035 
(1.545) 
8.260 
(1.171) 
7.966 
(1.277) 
Age 42.642 
(9.335) 
42.188 
(10.087) 
41.865 
(8.336) 
43.068 
(9.227) 
Female 0.738 
(0.440) 
0.665 
(0.473) 
0.724 
(0.448) 
0.776 
(0.418) 
Major depression, single episode 0.179 
(0.383) 
0.313 
(0.464) 
0.135 
(0.343) 
0.129 
(0.336) 
Major depression, recurrent 0.109 
(0.312) 
0.265 
(0.442) 
0.141 
(0.349) 
0.029 
(0.168) 
Dysthymia 0.264 
(0.441) 
0.313 
(0.464) 
0.460 
(0.500) 
0.187 
(0.390) 
Reactive depression 0.077 
(0.267) 
0.066 
(0.249) 
0.239 
(0.428) 
0.037 
(0.190) 
Depression NOS 0.370 
(0.483)  
0.044  
(0.206) 
0.025  
(0.155) 
0.617  
(0.486) 
Log Pre-Diagnosis Costs 4.568 
(2.622) 
4.301 
(2.836) 
4.892 
(2.686) 
4.602 
(2.490) 
Comorbidities 6.829 
(2.992) 
6.688 
(3.182) 
7.190 
(2.856) 
6.794 
(2.934) 
Mental Health Coinsurance Rate 0.126 
(0.095) 
0.140 
(0.121) 
0.120 
(.087) 
0.121 
(.083) 
Case Management 0.362 
(0.481) 
0.379 
(0.486) 
0.288 
(0.454) 
0.374 
(0.484) 
Source: Authors’ calculations.     
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Table 2: Psychotherapy Visits – Zero Inflated Negative Binomial Regression 
 
 
Coefficient Std. Error t-ratio P-value 
Marginal 
Effect Std. Error t-ratio P-value 
Constant  1.671 0.281 5.951 0.000 11.745 3.294 3.565 0.000
Age −0.013 0.005 −2.732 0.006 −0.094 0.065 −1.456 0.146
Female  
 
  
  
 
     
      
0.104 0.118 0.879 0.380 0.731 1.389 0.527 0.599
Major depression, single episode 0.090 0.159 0.564 0.573 0.629 1.862 0.338 0.736
Major depression, recurrent 
 
0.657 0.210 3.135 0.002 4.620 2.458 1.880 0.060
Dysthymia 0.253 0.115 2.193 0.028 1.775 1.350 1.314 0.189
Reactive depression 0.125 0.242 0.519 0.604 0.881 2.834 0.311 0.756
Log Pre-Diagnosis Costs 0.007 0.018 0.400 0.689 0.052 0.217 0.237 0.812
Anxiolytic Prescriptions 0.030 0.008 3.678 0.000 0.214 0.102 2.102 0.036
Comorbidities 0.010 0.018 0.562 0.574 0.072 0.217 0.333 0.739
Psychiatrist 0.950 0.201 4.737 0.000 6.676 2.353 2.838 0.005
Non-MD Mental Health Specialist 0.225 0.154 1.459 0.145 1.580 1.808 0.874 0.382
Plan Coinsurance Rate −0.444 0.621 −0.715 0.475 −3.122 7.282 −0.429 0.668
Case Management −0.069 0.099 −0.702 0.482 −0.487
  
1.157
 
−0.421
 
0.674
 Overdispersion Parameter 2.316 0.389 5.950 0.000
Zero Inflation Parameter −0.895 0.329 −2.723 0.006
Source: Authors’ calculations.
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Table 3: Antidepressant Prescriptions – Truncated Negative Binomial 
 
 
Coefficient Std. Error t-ratio P-value 
Marginal 
Effect Std. Error t-ratio P-value 
Constant  1.716 0.196 8.773 0.000 18.194 5.993 3.036 0.002
Age 
  
  
  
      
0.004 0.004 0.951 0.341 0.0490.043 0.877 0.381
Female −0.016 0.084 −0.196 0.845 −0.175 0.932 −0.187 0.851
Major depression, single episode 0.121 0.109 1.114 0.265 1.285 1.265 1.016 0.310
Major depression, recurrent 0.137 0.152 0.901 0.368 1.452 1.746 0.832 0.406
Dysthymia −0.136 0.100 −1.359 0.174 −1.438 1.216 −1.182 0.237
Reactive depression 0.048 0.159 0.300 0.764 0.505 1.761 0.286 0.775
Log Pre-Diagnosis Costs 0.003 0.014 0.202 0.840 0.031 0.160 0.193 0.847
Anxiolytic Prescriptions 0.035 0.014 2.552 0.011 0.369 0.194 1.906 0.057
Comorbidities 0.015 0.006 2.474 0.013 0.158 0.089 1.780 0.075
Psychiatrist 0.038 0.097 0.391 0.696 0.401 1.081 0.371 0.711
Non-MD Mental Health Specialist 0.049 0.108 0.456 0.648 0.521 1.207 0.432 0.666
Plan Coinsurance Rate 0.193 0.378 0.510 0.610 2.047 4.239 0.483 0.629
Case Management 0.326 0.079 4.136 0.000 3.452
 
1.446
 
2.387
 
0.017
 Overdispersion parameter 0.836 0.062 13.395 0.000
Source: Authors’ calculations.
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Table 4: Relapse – Logit Regression 
 
 
Coefficient Std. Error t-ratio P-value 
Marginal 
Effect Std. Error t-ratio P-value 
Constant −0.322 0.449 −0.717 0.473 0.052 0.072 −0.719 0.472
Age −0.013 0.009 −1.443 0.149 −0.002 0.001 −1.445 0.149
Female −0.338 0.189 −1.790 0.074 −0.054 0.030 −1.794 0.073
Major depression, single episode −0.103 0.258 −0.399 0.690 −0.017 0.041 −0.399 0.690
Major depression, recurrent −0.133 0.338 −0.392 0.695 −0.021 0.054 −0.392 0.695
Dysthymia 
 
 
0.076 0.221 0.343 0.732 0.0350.012 0.343 0.732
Reactive depression 0.176 0.335 0.524 0.600 0.028 0.054 0.524 0.600
Log Pre-Diagnosis Costs −0.015 0.032 −0.466 0.641 −0.002 0.005 −0.466 0.641
Anxiolytic Prescriptions 0.036 0.011 3.261 0.001 0.006 0.002 3.267 0.001
Comorbidities 0.077 0.029 2.617 0.009 0.0050.012 2.625 0.009
Psychiatrist −0.682 0.241 −2.829 0.005 −0.109 0.038 −2.851 0.004
Non-MD Mental Health Specialist −0.216 0.253 −0.853 0.393 −0.035 0.040 −0.854 0.393
Plan Coinsurance Rate −0.986 0.378 0.510 0.610 2.047 4.239 0.483 0.629
Case Management 0.565 0.165 3.420 0.001 0.091 0.026 3.450 0.001
Antidepressant Prescriptions −0.063 0.011 −5.945 0.000 −0.010 0.002 −6.229 0.000
Psychotherapy Visits 0.004 0.009 0.510 0.610 0.001 0.001 0.510 0.610
Source: Authors’ calculations.  
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